Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CircRNA detection kit for predicting neoadjuvant chemotherapy reactivity of triple-negative breast cancer (TNBC)

A triple-negative breast cancer and kit technology, applied in the field of biomedicine, can solve problems such as poor results, enlarged lesions, and decreased physical fitness of patients

Active Publication Date: 2020-03-27
GUANGDONG GENERAL HOSPITAL
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, neoadjuvant chemotherapy also has risks. Some patients do not respond well to neoadjuvant chemotherapy, which may increase the size of the lesion or decrease the patient's physical fitness, and may also lose the chance to cure the tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CircRNA detection kit for predicting neoadjuvant chemotherapy reactivity of triple-negative breast cancer (TNBC)
  • CircRNA detection kit for predicting neoadjuvant chemotherapy reactivity of triple-negative breast cancer (TNBC)
  • CircRNA detection kit for predicting neoadjuvant chemotherapy reactivity of triple-negative breast cancer (TNBC)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 Predicting the composition of the neoadjuvant chemotherapy response kit for triple-negative breast cancer (50 responses)

[0015] 1. DEPC water or enzyme-free water 10ml, double distilled water 10ml;

[0016] 2. Trizol 50ml;

[0017] 3. Chloroform 100ml;

[0018] 4. Isopropanol 100ml;

[0019] 5. 1ml of 5× reverse transcription buffer;

[0020] 6. 1ml of 25mM magnesium chloride;

[0021] 7. 1ml of 10mM base triphosphate deoxynucleotide;

[0022] 8. 5U / μl RAN enzyme inhibitor 500μl;

[0023] 9. 200U / μl MMLV reverse transcriptase 50μl or 25U / μl AMV enzyme 50μl;

[0024] 10. 2ml real-time quantitative PCR buffer;

[0025] 11. 5U / μl Taq polymerase 50μl;

[0026] 12. 50 μl of 5 μM hsa_circRNA_038632 specific PCR primers;

[0027] (1) The forward primer is 5'-AGAGCTGCATCATCCTTGCA3' (SEQ ID NO: 2),

[0028] (2) The reverse primer is 5'-TCTTGTGCAGCTCCAGGAGA-3' (SEQ ID NO: 3).

[0029] 13. 5μM β-actin-specific PCR primers 30μl

[0030](1) The forward primer...

Embodiment 2

[0034] Example 2 Detection of hsa_circRNA_038632 in tissue samples

[0035] 1. Extract tissue RNA

[0036] Take the tissue sample and add liquid nitrogen to the mortar to grind the sample; add 0.6ml Trizol to the mortar to grind the sample, grind it into a homogenous slurry and add it to the tube with a medicine spoon; add 0.4ml Trizol to the tube; add chloroform 200μl / ml Trizol In the tube, shake by hand for 15-30s, place on ice for 5min, centrifuge at 12000g at 4°C for 15min; carefully take the upper aqueous phase into a new tube, add pre-cooled isopropanol 0.5ml / ml Trizol and mix well, store in -20°C refrigerator Stand still for 20min, centrifuge at 12000g at 4°C for 10min; discard the supernatant, add 1-2ml of ethanol diluted with 75% DEPC water and mix well, centrifuge at 7500g at 4°C for 5min, discard the supernatant as much as possible, dry at room temperature for 5-10min, add DEPC water for 10- 20 μl of dissolved RNA. The concentration and quality of RNA were measure...

Embodiment 3

[0049] Example 3 Relationship between hsa_circRNA_038632 and responsiveness to neoadjuvant chemotherapy in patients with triple-negative breast cancer

[0050] The inventor detected the expression of hsa_circRNA_038632 in tumor tissues of 89 triple-negative breast cancer patients receiving neoadjuvant chemotherapy before treatment, and then performed postoperative pathological evaluation on each detected triple-negative breast cancer patient. According to the International Union Against Cancer (UICC) general efficacy evaluation criteria for solid tumors. Patients with curative effect pCR were defined as chemotherapy effective, and non-pCR patients were defined as chemotherapy ineffective / less sensitive. The included patients were all female, all of them were diagnosed as invasive breast cancer by hollow needle aspiration, and the pathological and immunohistochemical results showed triple negative type. Imaging tests confirmed no distant metastasis. All patients received 6 cy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides circRNA for predicting neoadjuvant chemotherapy sensitivity of triple-negative breast cancer (TNBC). The circRNA is hsa_circRNA_038632, with a nucleotide sequence shown in SEQ ID NO: 1. The invention further provides a kit for predicting neoadjuvant chemotherapy sensitivity of TNBC. The invention finds the correlation between the hsa_circRNA_038632 and reactivity of TNBC patients to neoadjuvant chemotherapy for the first time, and the reactivity of the TNBC patients to the neoadjuvant chemotherapy can be predicted by detecting the expression level of the hsa_circRNA_038632, so that determination of chemotherapy regimens for the TNBC patients is facilitated.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the use of a circular RNA detection kit to predict the neoadjuvant chemotherapy responsiveness of triple-negative breast cancer. Background technique [0002] Breast cancer is the female malignancy with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) refers to breast cancer with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). It accounts for 15%-20% of the whole breast cancer population. Compared with hormone receptor-positive or HER2-positive breast cancer, most triple-negative breast cancers are clinically characterized by aggressiveness, higher histological grade, poor prognosis, and visceral metastasis. Because triple-negative breast cancer lacks the expression of ER, PR and HER2 receptors, conventional endocrine therapy and HER2-targeted therapy are not sensitive, chemother...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/178C12Q2600/106C12Q2600/158
Inventor 陈博廖宁代大年肖伟锴赖建国郭丽萍韦光楠
Owner GUANGDONG GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com